Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wra...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

LuckEtradER Apr. 3 at 11:14 PM

$AXGN 👀

0 · Reply

dustin1101 Apr. 2 at 10:15 PM

$AXGN FWIW what AI thinks are likely buyers in the event of an aquisition, and why..

0 · Reply

dustin1101 Apr. 2 at 6:01 PM

$AXGN awesome bull bias the last few days. $35 LFG!

0 · Reply

dustin1101 Apr. 1 at 4:02 PM

$AXGN Chart remains solid. ~34 and 36 levels are what you call stacked catalysts. Break these with volume and this heads to the $40-45 range IMO.

0 · Reply

dustin1101 Mar. 31 at 3:41 PM

$AXGN Volume spike 👀 100K+ cleared out the offer. Straight up 75 cents..

0 · Reply

OlynykClinic Mar. 29 at 5:17 AM

$AXGN AXGN sells its nerve repair products to hundreds of hospitals and surgeons. Furthermore, they recently expanded their commercial insurance coverage to over 64% of covered lives (adding roughly 18 million covered lives recently). Their revenue is spread across thousands of individual procedures, making their cash flow highly resilient and predictable. The healthcare sector moves slowly but predictably. Once a medical device is approved by the FDA and covered by insurance companies, doctors do not stop using it overnight. AXGN has a known catalyst—an anticipated FDA BLA (Biologics License Application) approval for its Avance Nerve Graft by late 2025. If that hits, the path to $40 is a standard mathematical repricing.

0 · Reply

dustin1101 Mar. 27 at 3:29 PM

$AXGN Added 1600 back here under $31. ~$1.50 off yesterday’s bid vacuum close on peanut volume. Easy.

0 · Reply

dustin1101 Mar. 24 at 3:23 PM

$AXGN If the market continues to reverse here on a more positive outlook on the Iran conflict.. this is in good shape with a higher low set. Lots of profit taking last week by traders thinking a mkt washout was coming yesterday. Look at what there is for what's probably dark pool (printed just after close) Who wants back in?

0 · Reply

dustin1101 Mar. 16 at 2:55 PM

$AXGN might just march on up to give $35 a tap soon.

0 · Reply

dustin1101 Mar. 13 at 2:51 PM

$AXGN Nice morning to make a flip. Sold as high as 33.83. 500 shares there. Added most back near 32.

1 · Reply

Market Cap	1.79B
Revenue (ttm)	225.21M
Net Income (ttm)	-15.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6.97%
Debt to Equity Ratio	0.39

Volume	615,400
Avg Vol	1,024,246
Day's Range	N/A - N/A
Shares Out	51.90M
Stochastic %K	97%
Beta	0.98
Analysts	Strong Sell
Price Target	$40.55